Test Name Result AB Normal Range Units
IGG 466 L 600-1700 MG/DL
IGM 31 L 35-290 MG/DL
IGA 408 H 40-400 MG/DL
Electrophoresis
The SPE pattern demonstrates two bands of restricted mobility in the gamma region.
Immunofix, Serum
Monoclonal component typed as IgA Lambda. Concentration of monoclonal protein determined by serum protein electrophoresis is 0.4 g/dL.
Monoclonal component typed as IgA Lambda. Concentration of monoclonal protein determined by serum protein electrophoresis is 0.3 g/dL.
*Suggestive of a monoclonal component typed as IgG Kappa. Concentration of monoclonal protein is too low to accurately quantify.
* This is new! Previously, I’ve only ever had just two m-spikes. That’s not enough? I vaguely remember seeing this on one other report, so maybe it’s something that comes and goes. In any case, it’s not enough to measure, so I’m not alarmed.
Serum Free Light Chain Assay
Test Name Result AB Normal Range Units
Kappa Free, Serum 0.1380 L 0.33-1.94 mg/dL
Lambda Free, Serum 1.24 0.57-2.63 mg/dL
K/L FLC Ratio 0.1113 L 0.26-1.65 mg/dL
I don’t have a lot to blog about here because my myeloma has been stable since last fall. There’s not much there at all. If you don’t have myeloma, I have only a little bit more than you do.
These labs were done 12/08/2008
IFE SERUM
(2) MONOCLONAL IgA-LAMBDAS DETECTED BY IFE.
SPE M-SPIKE 1 0.17 g/dL
SPE M-SPIKE 2 0.12 g/dL
IG FREE LIGHT CHAINS SERUMReference
IG FREE LIGHT CHAIN KAPPA *0.16mg/dL [0.33-1.94]
IG FREE LIGHT CHAIN LAMBDA 1.85mg/dL [0.57-2.63]
IG FLC KAPPA/LAMBDA RATIO *0.09 [0.26-1.65]
IMMUNOGLOBULIN PROFILE
IMMUNOGLOBULIN G *374mg/dL [588-1573]
TEST REPEATED TO CONFIRM
IMMUNOGLOBULIN A *415mg/dL [46-287]
TEST REPEATED TO CONFIRM
IMMUNOGLOBULIN M *31mg/dL [57-237]
TEST REPEATED TO CONFIRM
IMMUNOGLOBULIN E 13 IU/mL [4-269]
Special Edition: Multiple Myeloma Series
Upcoming Webcast:
This year’s American Society of Hematology meeting in Atlanta has brought many exciting new developments. Join us this Friday for our discussion with two experts, Dr. Brian Durie, Founder, a Myeloma Specialist and Chairman of the Board for the International Myeloma Foundation and Dr. James Berenson, Founder, President & Chief Executive Officer of the Institute for Myeloma and Bone Cancer Research. You’ll hear the latest groundbreaking news from the meeting and what these two renowned experts are excited about in Myeloma treatment and research.
“The Latest Myeloma News from the American Society of Hematology Meeting”
Friday, December 14, 2007, 2:00 pm Eastern (11:00 am Pacific)
Sponsored through an educational grant from Millennium Pharmaceuticals, Inc.
For a schedule of upcoming webcasts, to listen to recent myeloma program replays, and for further information, visit http://www.patientpower.info/specialeditionlymphoma.asp.
Featured Guests:
Brian G.M. Durie, M.D. is Chairman of the Board of the International Myeloma Foundation and a myeloma specialist at Cedars-Sinai Comprehensive Cancer Center in Los Angeles. He is also a member of the IMF Scientific Advisory Board. Dr. Durie is the recipient of the Leukemia Society of America Scholar award and the U.S. Hematologic Research Foundation Annual Award, among many others.
James Berenson, M.D. is the Founder, President and CEO of the non-profit Institute for Myeloma and Bone Cancer Research (www.imbcr.org) and Berenson Oncology (www.berensononcology.com) in Los Angeles, California. A leading physician-scientist, Dr. Berenson has specialized in cutting-edge research related to myeloma and metastatic bone disease both in the lab and with patients for 20+ years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives. His latest initiative, “The Cure Myeloma Project” enlists the work of a full-time research staff engaging in rigorous pre-clinical and clinical trials, using human myeloma cells.
Andrew Schorr: Host and eleven-year CLL survivor
HOW TO PARTICIPATE:
Listen live at http://www.patientpower.info/specialeditionmyeloma.asp
Call in live 877-711-5611 or Email questions to andrew@patientpower.info
ABOUT PATIENT POWER:
Patient Power is a weekly show hosted by Andrew Schorr, ten-year leukemia survivor, patient educator and patient advocate. The show features renowned medical experts on topics that include cancer, pain, diabetes, and heart specialists, as well as experts in clinical trials and top pharmacists. The show serves to bring patients together in a radio and Internet community to provide information about available treatment options. Patient Power takes questions from callers and Internet listeners on topics such as how to find the right doctor, how to advocate for effectively, when to get a second opinion from a specialist and how to evaluate one treatment option over another.
Loading ...
